Restricted Calorie Ketogenic Diet for the Treatment of Glioblastoma Multiforme
Abstract
Glioblastoma multiforme is the most common malignant primary brain tumor in adults and generally considered to be universally fatal. Glioblastoma multiforme accounts for 12% to 15% of all intracranial neoplasms and affects 2 to 3 adults per every 100,000 in the United States annually. In children glioblastoma multiforme accounts for only approximately 7% to 9% of central nervous system tumors. The mean survival rate in adults after diagnosis ranges from 12 to 18 months with standard therapy and 3 to 6 months without therapy. The prognosis in children is better compared to adult tumor onset with a mean survival of approximately 4 years following gross total surgical resection and chemotherapy. There have been few advances in the treatment of glioblastoma multiforme in the past 40 years beyond surgery, radiotherapy, chemotherapy, and corticosteroids. For this reason a restrictive calorie ketogenic diet, similar to that used in children to control drug resistant seizure activity, has been advanced as an alternative adjunctive treatment to help prolonged survival. This article reviews the science of tumor metabolism and discusses the mechanism of calorie restriction, cellular energy metabolism, and how dietary induced ketosis can inhibit cancer cell’s energy supply to slow tumor growth.
Get full access to this article
View all access and purchase options for this article.
References
1. Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted calorie ketogenic diet: case report. Nutr Metab. 2010;7:33.
2. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100:2235–2241.
3. Tso CL, Shintaku P, Chen J, et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006;4:607–619.
4. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17:362–375.
5. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466.
6. Mason WP, Maestro RD, Eisenstat D, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14:110–117.
7. Kitange GJ, Carlson BL, Schroeder MA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-Oncology. 2009;11:281–291.
8. Hegi ME, Diserens A, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
9. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–530
10. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314.
11. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg Effect in carcinogenesis. J Biol Chem. 2002;277:23111–23115.
12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033.
13. Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Metabolic management of brain cancer. Biochimica et Biophysica Acta. 2011;1807:577–594.
14. Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: a systematic review of efficacy. Pediatrics. 2000;105:e46.
15. Freeman JM, Kossoff EH, Hartman AL. The ketogenic diet: one decade later. Pediatrics. 2007;119:535–543.
16. Hartman AL, Vining AP. Clinical aspects of the ketogenic diet. Epilepsia. 2007;48:31–42.
17. Sirven J, Whedon B, Caplan D, et al. The ketogenic diet for intractable epilepsy in adults: preliminary results. Epilepsia. 1999;40:1721–1726.
18. Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab. 2005;2:30.
19. Seyfried TN, Mukherjee P, Kalamian M, Zuccoli G. The restricted calorie ketogenic diet: an alternative treatment strategy for glioblastoma multiforme. Treatment Strategies—Oncol. 2011:1–12.
20. Potts R. Humanity’s Descent: The Consequences of Ecological Instability. New York, NY: William Morrow; 1996.
21. Seyfried TN. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. Hoboken, NJ: John Wiley; 2012.
22. Seyfried TN, Shelton LM, Mukherjee P. Does existing standard of care increase glioblastoma energy metabolism? Lancet Oncol. 2010;11:811–813.
23. McCay CM, Crowell MF, Maynard MA. The effect of retarded growth upon the length of life span and upon the ultimate body size. J Nutr. 1935;10:63–69.
24. Guarente L. Mitochondria—a nexus for aging, calorie restriction, and sirtuins? Cell. 2008;132:171–176.
25. Kennedy BK, Austriaco NR, Zhang J, Guarente L. Mutations in silencing gene SIR4 can delay aging in S. cerevisiae. Cell. 1995;80:485–496.
26. Sinclair D. Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev. 2005;126:987–1002.
27. Lewis KN, Mele J, Hayes JD, Beffenstein R. Nrf2, a guardian of healthspan and gatekeeper of species longevity. Integr Comp Biol. 2010;50:829–843.
28. Park LK, Friso S, Chio SW. Nutritional influences on epigenetics and age-related diseases. Proc Nutr Soc. 2012;71:75–83.
29. Marsh J, Mukherjee P, Seyfried TN. Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted calorie ketogenic diet. Nutr Metab. 2008;5:33.
30. Zhu Z, Jiang W, McGinley JN, Thompson HJ. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 2005;65:7023–7030.
31. Minor RK, Smith DL, Sossong AM, et al. Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol Appl Pharmacol. 2010;243:332–339.
32. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2002;140:490.
33. Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001;7:2292–2300.
34. Otto C, Kaemmerer U, Illert B, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer. 2008;8:122.
35. Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer. 2002;86:1615–1621.
36. Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr. 1995;14:202–208.
37. Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab. 2011;8:54.
38. Keijer J, Bekkenkamp-Grovenstein M, Venema D, Dommels Y. Bioactive food components, cancer cell growth limitation and reversal of glycotic metabolism. Biochimica et Biophysica Acta. 2011;1807:697–706.
39. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by reseveratrol: in vitro and in vivo studies and the underlying mechanism (review). Intl J Oncol. 2003;23:17–28.
40. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24:2783–2840.
41. Nagle DG, Zhou Y. Natural product-based inhibitors of Hypoxia-inducible Factor-1 (HIF-1). Curr Drug Targets. 2006;7:355–359.
42. Hardman EW. Omega-3 fatty acids to augment cancer therapy. J Nutr. 2002;132:3508–3512.
43. Novotny L, Rauko P, Cojocel C. Alpha-lipoic acid: the potential use in cancer therapy. Neoplasma. 2008;55:81–86.
44. Wenzel U, Nickel A, Daniel H. α-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-generation. Apoptosis. 2005;10:359–368.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: May 13, 2013
Issue published: August 2013
Keywords
PubMed: 23670248
Authors
Author Contributions
All authors contributed equally to the composition of this article.
Metrics and citations
Metrics
Article usage*
Total views and downloads: 1119
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 19 view articles Opens in new tab
Crossref: 16
-
Régime cétogène et cancer
-
MR-Spectroscopy and Survival in Mice with High Grade Glioma Undergoing...
-
Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-...
-
SP1-Regulated Non-Coding RNA SNHG22 Promotes Ovarian Cancer Growth and...
-
Treatment of glioblastoma multiforme with “classic” 4:1 ketogenic diet...
-
Cancer diets for cancer patients: Lessons from mouse studies and new i...
-
Treatment of malignant gliomas with ketogenic or caloric restricted di...
-
Chemically Modified Variants of Fenofibrate with Antiglioblastoma Pote...
-
A novel metabolism-based phenotypic drug discovery platform in zebrafi...
-
Role of ketogenic metabolic therapy in malignant glioma: A systematic ...
-
Combination of metronomic cyclophosphamide and dietary intervention in...
-
Treatment of glioma patients with ketogenic diets: report of two cases...
-
Glioblastoma multiforme: emerging treatments and stratification marker...
-
Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calo...
-
Roles of Caloric Restriction, Ketogenic Diet and Intermittent Fasting ...
-
A decade of the modified Atkins diet (2003–2013): Results, insights, a...
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
